{
  "id": "8ff09c0806783f89",
  "title": "Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron Eylea in Phase 3 Test",
  "description": "20260217T233000Z",
  "content": "",
  "source": "medcitynews.com",
  "source_url": "https://medcitynews.com/2026/02/ocular-therapeutix-wet-age-related-macular-degeneration-amd-axpaxli-tki-ocul/",
  "published_at": "20260217T233000Z",
  "fetched_at": "2026-02-18T00:30:07.542614+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda",
    "drug"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://medcitynews.com/2026/02/ocular-therapeutix-wet-age-related-macular-degeneration-amd-axpaxli-tki-ocul/",
    "url_mobile": "",
    "title": "Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron Eylea in Phase 3 Test",
    "seendate": "20260217T233000Z",
    "socialimage": "https://medcitynews.com/wp-content/uploads/sites/7/2021/10/GettyImages-175133840.jpg",
    "domain": "medcitynews.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}